Gefitinib/chloroquine-liposome-microbubble complexes as ultrasound-triggered therapeutic particles for head and neck squamous cell carcinoma in vitro

doi:10.19439/j.sjos.2020.02.011

Abstract

Abstract: PURPOSE: To explore a kind of therapeutic particle of targeted, fewer side effects, both with value of diagnosis and treatment for head and neck squamous cell carcinoma(HNSCC) in vitro. METHODS: Gefitinib-liposome-microbubble model and chloroquine liposome-microbubble model were prepared separately. HN-30 cells were divided into 5 groups: PBS, GE-Lipo+CQ-Lipo, MB-GE-Lipo, MB-CQ-Lipo, MB-GE-Lipo+ MB-CQ-Lipo. MTS kit was used to detect the inhibitory effect of cell proliferation in each group. SPSS17.0 software package was used to analyze the data. RESULTS: When EPC: Chol=2:1, there was no significant difference in the entrapment efficiency between 2:1 and 8:1 group (P>0.05). Compared with 5:1,10:1,20:1 group, there was significant difference in the entrapment efficiency of 2:1 group (P<0.05). Among group 5:1, 8:1, 10:1, and 20:1, compared with each other, there was no significant difference (P>0.05). For HN-30 cells, there was significant difference(P<0.05) between MB-GE-Lipo+ MB-CQ-Lipo group and PBS group. There was no significant difference between MB-GE-Lipo+ MB-CQ-Lipo group and MB-GE-Lipo group (P>0.05). CONCLUSIONS: When EPC:Chol=5:1, the EE of GE-Lipo was higher, the ratio of cholesterol was appropriate, and the liposome was more stable. The inhibitory effect of gefitinib liposome-microbubbles + chloroquine liposome-microbubbles combined with ultrasound on HN-30 cell proliferation was significant.

Key words: Microbubble, Targeting, EGFR, Head and neck squamous cell carcinoma

CLC Number:

R739.8

ZHOU Lu, GONG Xia, XIONG Ping. Gefitinib/chloroquine-liposome-microbubble complexes as ultrasound-triggered therapeutic particles for head and neck squamous cell carcinoma in vitro[J]. Shanghai Journal of Stomatology, 2020, 29(2): 168-173.

References

[1] Gage KL, Thomas K, Jeong D, et al.Multimodal imaging of head and neck squamous cell carcinoma[J]. Cancer Control, 2017, 24(2): 172-179.
[2] Muratori L, La Salvia A, Sperone P, et al.Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review[J]. Crit Rev Oncol Hematol, 2019, 139: 41-52.
[3] Guidi A, Codecà C, Ferrari D, et al.Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review[J]. Med Oncol, 2018, 35(3): 35-37.
[4] Bossi P, Alfieri S, Strojan P, et al.Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature[J]. Crit Rev Oncol Hematol, 2019, 137(1): 84-91.
[5] Santuray RT, Johnson DE, Grandis JR.New therapies in head and neck cancer?[J]. Trends Cancer, 2018, 4(5): 385-396.
[6] Fung C, Grandis J.Emerging drugs to treat squamous cell carcinomas of the head and neck[J]. Expert Opin Emerg Drugs, 2010, 15(3): 355-373.
[7] Kozakiewicz P, Grzybowska-Szatkowska L.Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)[J]. Oncol Lett, 2018, 15(5): 7497-7505.
[8] Su Y, Cui J, Xu D, et al.p16(INK4a) status and survival benefit of EGFR inhibitors in head and neck squamous cell cancer: A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2018, 124: 11-20.
[9] Bossi P, Resteghini C, Paielli N, et al.Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma[J]. Oncotarget, 2016, 7(45): 74362-74379.
[10] Kelkar SS, Reineke TM.Theranostics: combining imaging and therapy[J]. Bioconjug Chem, 2011, 22(10): 1879-1903.
[11] Blanco I.Polysiloxanes in theranostics and drug delivery: a review[J]. Polymers(Basel), 2018, 10(7): 755-768.
[12] Arranja AG, Pathak V, Lammers T, et al.Tumor-targeted nanomedicines for cancer theranostics[J]. Pharmacol Res, 2017, 115: 87-95.
[13] Boulikas T.Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin[J]. Expert Opin Investig Drugs, 2009, 18(8): 1197-1218.
[14] Sorace AG, Warram JM, Umphrey H, et al.Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer[J]. J Drug Target, 2012, 20(1): 43-54.
[15] Sennoga CA, Kanbar E, Auboire L, et al.Microbubble-mediated ultrasound drug-delivery and therapeutic monitoring[J]. Expert Opin Drug Deliv, 2017, 14(9): 1031-1043.
[16] Yan F, Li L, Deng Z, et al.Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers[J]. J Control Release, 2018, 166(3): 246-255.
[17] Nguyen AT, Wrenn SP.Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2014, 6(3): 316-325.
[18] Akbarzabeh A, Rezaei S, Davaran S, et al.Liposome: classification, preparation, and applications[J]. Nanoscale Res Lett, 2013, 8(1): 102-110.
[19] Kapoor M, Lee SL, Tyner KM, et al.Liposomal drug product development and quality: current US experience and perspective[J]. AAPS J, 2017, 19(3): 632-641.
[20] Rothenberg SM, Ellisen LW.The molecular pathogenesis of head and neck squamous carcinoma[J]. J Clin Invest, 2012, 122(6): 1951-1957.
[21] Fung C, Grandis JR.Emerging drugs to treat squamous cell carcinomas of the head and neck[J]. Expert Opin Emerg Drugs, 2010, 15(3): 355-373.
[22] Hartmann S, Neckel N, Seher A, et al.Erlotinib and gefitinib responsiveness in head and neck cancer cell lines-a comparing analysis with cetuximab[J]. Clin Oral Investig, 2016, 20(4): 759-769.
[23] Jutten B, Rouschop KM.EGFR signaling and autophagy dependence for growth, survival, and therapy resistance[J]. Cell Cycle, 2014, 13(1): 42-51.
[24] Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al.Principles and current strategies for targeting autophagy for cancer treatment[J]. Clin Cancer Res, 2011, 17(4): 654-666.
[25] Jia L, Wang J, Wu T, et al.In vitro and in vivo antitumor effects of chloroquine on oral squamous cell carcinoma[J]. Mol Med Rep, 2017, 16(5): 5779-5786.
[26] Bao SP, Thrall BD, Miller DL.Transfection of a reporter plasmid into cultured cells by sonoporation in vitro[J]. Ultrasound Med Biol, 1997, 23(6): 953-959.